- The project team aims to create a wound dressing that provides an early indication of infection at point of care (PoC).
- This would significantly enhance clinical decision-making – with the capability to rapidly distinguish the bacterial Clinical Colonisation Threshold (TREAT) from sub-clinical colonisation (DON’T TREAT).
Benefits of the project include:
- ‘Front line’ nursing and clinical care staff in secondary care settings involved in infection control and the treatment of burn patients.
- Clinical microbiologists based in secondary care settings with responsibility for infection diagnosis.
- Infection control teams responsible for monitoring and preventing hospital acquired infections can use this technology.
- Academics and other scientists seeking to understand the pathogenesis of wound infections, and undertaking translational research.
- There is great potential to adapt this incredible technology to detect infection in other acute and chronic wounds.
2018 – 2019: GMP Manufacture and upscaling
2020 – 2021: Regulatory and ethical compliance, first human trial
- The first image shows the SmartWound bandage on the skin, not fluorescing as it is not infected. The second shows the bandage on the skin fluorescing due to being infected with bacteria.
- This image shows the dressing’s response to infection. The first image is at 0 minutes, the second at 2 minutes. You can see how the dressing has an increase in fluorescence with time.
- This shows the bandage with no fluorescence, as it would appear in the packaging.
Find out all about Smart Wounds on Toby Jenkins’ website: http://www.smartwound.co.uk. All information taken directly from the website.